搜索医生

Jayant A. Talwalkar, M.D., M.P.H.

  1. Transplant Hepatologist
预约门诊

出版物

  1. Padkins MR, Kamboj AK, Talwalkar JA. Progressive Weakness and Encephalopathy in a 34-Year-Old Woman. Clin Gastroenterol Hepatol. 2021 Aug; 19 (8):A24 Epub 2020 May 08
    View PubMed
  2. Krishnamoorthi R, Hargraves I, Gopalakrishnan N, Blevins CH, Priyan H, Johnson ML, Maixner KA, Wang KK, Katzka DA, Talwalkar JA, LeBlanc A, Iyer PG. Development and Pilot Testing of Decision Aid for Shared Decision Making in Barrett's Esophagus With Low-Grade Dysplasia. J Clin Gastroenterol. 2021 Jan; 55 (1):36-42
    View PubMed
  3. Asrani SK, Hall L, Hagan M, Sharma S, Yeramaneni S, Trotter J, Talwalkar J, Kanwal F. Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am J Gastroenterol. 2019 Jan; 114 (1):98-106
    View PubMed
  4. Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. Hepatology. 2018 Dec; 68 (6):2230-2238 Epub 2018 Sept 20
    View PubMed
  5. Okafor PN, Swanson K, Shah N, Talwalkar JA. Endoscopic ultrasound for rectal cancer staging: A population-based study of utilization, impact on treatment patterns, and survival. J Gastroenterol Hepatol. 2018 Aug; 33 (8):1469-1476 Epub 2018 Mar 14
    View PubMed
  6. Venkatesh SK, Talwalkar JA. When and how to use magnetic resonance elastography for patients with liver disease in clinical practice. Am J Gastroenterol. 2018 Jul; 113 (7):923-926
    View PubMed
  7. Mathur AK, Talwalkar J. Quality measurement and improvement in liver transplantation. J Hepatol. 2018 Jun; 68 (6):1300-1310 Epub 2018 Mar 17
    View PubMed
  8. Chirapongsathorn S, Krittanawong C, Enders FT, Pendegraft R, Mara KC, Borah BJ, Visscher SL, Loftus CG, Shah VH, Talwalkar JA, Kamath PS. Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis. Hepatol Commun. 2018 Feb; 2 (2):188-198 Epub 2018 Jan 18
    View PubMed
  9. Mouchli MA, Singh S, Loftus EV Jr, Boardman L, Talwalkar J, Rosen CB, Heimbach JK, Wiesner RH, Hasan B, Poterucha JJ, Watt KD, Kymberly WD. Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis. Transplantation. 2017 Aug; 101 (8):1859-1866
    View PubMed
  10. Chen J, Yin M, Talwalkar JA, Oudry J, Glaser KJ, Smyrk TC, Miette V, Sandrin L, Ehman RL. Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. Radiology. 2017 May; 283 (2):418-428 Epub 2016 Nov 18
    View PubMed
  11. Okafor PN, Stobaugh DJ, Nnadi AK, Talwalkar JA. Determinants of Palliative Care Utilization Among Patients Hospitalized With Metastatic Gastrointestinal Malignancies. Am J Hosp Palliat Care. 2017 Apr; 34 (3):269-274 Epub 2016 July 11
    View PubMed
  12. Hilscher MB, Odell LJ, Myhre LJ, Prokop L, Talwalkar J. The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions. J Clin Pharm Ther. 2016 Dec; 41: (6)587-591.
    View PubMed
  13. Chirapongsathorn S, Talwalkar JA, Kamath PS. Readmission in Cirrhosis: a Growing Problem. Curr Treat Options Gastroenterol. 2016 Jun; 14 (2):236-46
    View PubMed
  14. Okafor PN, Stobaugh DJ, Wong Kee Song LM, Limburg PJ, Talwalkar JA. Socioeconomic Inequalities in the Utilization of Colorectal Stents for the Treatment of Malignant Bowel Obstruction. Dig Dis Sci. 2016 Jun; 61 (6):1669-76 Epub 2016 Jan 06
    View PubMed
  15. Okafor PN, Stobaugh DJ, van Ryn M, Talwalkar JA. African Americans Have Better Outcomes for Five Common Gastrointestinal Diagnoses in Hospitals With More Racially Diverse Patients. Am J Gastroenterol. 2016 May; 111 (5):649-57 Epub 2016 Mar 22
    View PubMed
  16. Chirapongsathorn S, Talwalkar JA, Kamath PS. Strategies to Reduce Hospital Readmissions. Semin Liver Dis. 2016 May; 36 (2):161-6 Epub 2016 May 12
    View PubMed
  17. Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016 May; 26 (5):1431-40 Epub 2015 Aug 28
    View PubMed
  18. Okafor PN, Chiejina M, de Pretis N, Talwalkar JA. Secondary analysis of large databases for hepatology research. J Hepatol. 2016 Apr; 64: (4)946-56.
    View PubMed
  19. Meier SK, Shah ND, Talwalkar JA. Adapting the Patient-centered Specialty Practice Model for Populations With Cirrhosis. Clin Gastroenterol Hepatol. 2016 Apr; 14: (4)492-6.
    View PubMed
  20. Chawla KS, Talwalkar JA, Keach JC, Malinchoc M, Lindor KD, Jorgensen R. Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH). BMJ Open Gastroenterol. 2016; 3 (1):e000069 Epub 2016 Mar 16
    View PubMed
  21. Juliusson G, Imam M, Bjornsson ES, Talwalkar JA, Lindor KD. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016; 51: (6)745-52.
    View PubMed
  22. Yao X, Sangaralingham LR, Ross JS, Shah ND, Talwalkar JA. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. Am J Manag Care. 2016; 22: (6)e224-32.
    View PubMed
  23. Yin M, Glaser KJ, Talwalkar JA, Chen J, Manduca A, Ehman RL. Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations. Radiology. 2016 Jan; 278 (1):114-24 Epub 2015 July 08
    View PubMed
  24. Dhanasekaran R, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep. 2015 Sep; 17 (9):34
    View PubMed
  25. Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH, US Drug-Induced Liver Injury Network Investigators. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol. 2015 Sep; 13 (9):1676-82.e1 Epub 2015 Feb 24
    View PubMed
  26. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J, United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015 Jun; 148 (7):1340-52.e7 Epub 2015 Mar 06
    View PubMed
  27. Venkatesh SK, Yin M, Takahashi N, Glockner JF, Talwalkar JA, Ehman RL. Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. Abdom Imaging. 2015 Apr; 40 (4):766-75
    View PubMed
  28. Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015 Mar; 13 (3):440-451.e6 Epub 2014 Nov 20
    View PubMed
  29. Foureau DM, Walling TL, Maddukuri V, Anderson W, Culbreath K, Kleiner DE, Ahrens WA, Jacobs C, Watkins PB, Fontana RJ, Chalasani N, Talwalkar J, Lee WM, Stolz A, Serrano J, Bonkovsky HL. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol. 2015; 180(1):40-51.
    View PubMed
  30. Papalavrentios L, Sinakos E, Chourmouzi D, Hytiroglou P, Drevelegas K, Constantinides M, Drevelegas A, Talwalkar J, Akriviadis E. Value of 3 Tesla diffusion-weighted magnetic resonance imaging for assessing liver fibrosis. Ann Gastroenterol. 2015 Jan-Mar; 28 (1):118-123
    View PubMed
  31. Hagan M, Asrani SK, Talwalkar J. Non-invasive assessment of liver fibrosis and prognosis. Expert Rev Gastroenterol Hepatol. 2015; 9: (10)1251-60.
    View PubMed
  32. Talwalkar JA. Overview of health care delivery and policy research in hepatology and liver transplantation. Clin Liver Dis (Hoboken). 2014 Dec; 4 (6):141-142 Epub 2015 Jan 20
    View PubMed
  33. Talwalkar JA. Innovative care delivery models for the clinical practice of hepatology. Clin Liver Dis (Hoboken). 2014 Dec; 4 (6):146-148 Epub 2015 Jan 20
    View PubMed
  34. Imam MH, Eaton JE, Puckett JS, Loftus EV Jr, Mathis KL, Gossard AA, Talwalkar JA, Lindor KD. Neoplasia in the ileoanal pouch following colectomy in patients with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis. 2014 Oct; 8: (10)1294-9.
    View PubMed
  35. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, Seeff LB, Serrano J, Sherker AH, Stolz A, Talwalkar J, Vega M, Vuppalanchi R. Liver injury from herbals and dietary supplements in the us drug-induced liver injury network. Hepatology. 2014 Oct; 60(4):1399-408.
    View PubMed
  36. Singh S, Eaton JE, Murad MH, Tanaka H, Iijima H, Talwalkar JA. Accuracy of spleen stiffness measurement in detection of esophageal varices in patients with chronic liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Jun; 12 (6):935-45.e4 Epub 2013 Sept 18
    View PubMed
  37. Talwalkar JA. Health services and policy research in hepatology. Curr Opin Gastroenterol. 2014 May; 30 (3):272-8
    View PubMed
  38. Eaton JE, Gossard AA, Talwalkar JA. Recall processes for biliary cytology in primary sclerosing cholangitis. Curr Opin Gastroenterol. 2014 May; 30(3):287-94.
    View PubMed
  39. Talwalkar JA. Potential impacts of the Affordable Care Act on the clinical practice of hepatology. Hepatology. 2014 May; 59(5):1681-7. Epub 2014 Mar 31.
    View PubMed
  40. Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Ann Hepatol. 2014 May-Jun; 13 (3):384-9
    View PubMed
  41. Asrani SK, Talwalkar JA, Kamath PS, Shah VH, Saracino G, Jennings L, Gross JB, Venkatesh S, Ehman RL. Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol. 2014 May; 60 (5):934-9 Epub 2013 Dec 19
    View PubMed
  42. Talwalkar JA, Oxentenko AS, Katzka DA. Health care-delivery research-training opportunities in gastroenterology and hepatology. Gastroenterology. 2014 Apr; 146 (4):878-83 Epub 2014 Feb 21
    View PubMed
  43. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH, Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014 Feb; 59: (2)661-70.
    View PubMed
  44. Singh S, Nagpal SJ, Murad MH, Yadav S, Kane SV, Pardi DS, Talwalkar JA, Loftus EV Jr. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Feb; 12 (2):210-8 Epub 2013 May 02
    View PubMed
  45. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014 Jan; 89: (1)95-106.
    View PubMed
  46. Gossard AA, Talwalkar JA. Cholestatic liver disease. Med Clin North Am. 2014 Jan; 98 (1):73-85 Epub 2013 Oct 20
    View PubMed
  47. Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology. 2013 Dec; 58(6):2142-52. Epub 2013 Oct 18.
    View PubMed
  48. Overby CL, Pathak J, Gottesman O, Haerian K, Perotte A, Murphy S, Bruce K, Johnson S, Talwalkar J, Shen Y, Ellis S, Kullo I, Chute C, Friedman C, Bottinger E, Hripcsak G, Weng C. A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury. J Am Med Inform Assoc. 2013 Dec; 20(e2):e243-52. Epub 2013 Jul 09.
    View PubMed
  49. Singh S, Varayil JE, Loftus EV Jr, Talwalkar JA. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl. 2013 Dec; 19(12):1361-9.
    View PubMed
  50. Barr Fritcher EG, Voss JS, Jenkins SM, Lingineni RK, Clayton AC, Roberts LR, Halling KC, Talwalkar JA, Gores GJ, Kipp BR. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol. 2013 Dec; 121(12):708-17. Epub 2013 Jul 09.
    View PubMed
  51. Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, Kamath PS, Talwalkar JA. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013 Dec; 11 (12):1573-84.e1-2; quiz e88-9 Epub 2013 Aug 15
    View PubMed
  52. Eaton JE, Smyrk TC, Imam M, Pardi DS, Loftus EV Jr, Owens VL, Talwalkar JA. The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation. Aliment Pharmacol Ther. 2013 Oct; 38 (8):977-87 Epub 2013 Aug 29
    View PubMed
  53. Imam MH, Talwalkar JA, Lindor KD. Clinical management of autoimmune biliary diseases. J Autoimmun. 2013 Oct; 46:88-96 Epub 2013 July 13
    View PubMed
  54. Yin M, Kolipaka A, Woodrum DA, Glaser KJ, Romano AJ, Manduca A, Talwalkar JA, Araoz PA, McGee KP, Anavekar NS, Ehman RL. Hepatic and splenic stiffness augmentation assessed with MR elastography in an in vivo porcine portal hypertension model. J Magn Reson Imaging. 2013 Oct; 38 (4):809-15 Epub 2013 Feb 15
    View PubMed
  55. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013 Sep; 145 (3):521-36 Epub 2013 July 01
    View PubMed
  56. Singh S, Loftus EV Jr, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol. 2013 Sep; 108 (9):1417-25 Epub 2013 July 30
    View PubMed
  57. Dzyubak B, Glaser K, Yin M, Talwalkar J, Chen J, Manduca A, Ehman RL. Automated liver stiffness measurements with magnetic resonance elastography. J Magn Reson Imaging. 2013 Aug; 38 (2):371-9 Epub 2012 Dec 19
    View PubMed
  58. Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol. 2013 Aug; 11 (8):898-907 Epub 2013 Feb 27
    View PubMed
  59. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 2013 Aug; 268 (2):411-9 Epub 2013 Apr 05
    View PubMed
  60. Singh S, Khanna S, Pardi DS, Loftus EV Jr, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013 Jul; 19 (8):1631-8
    View PubMed
  61. Imam MH, Talwalkar JA, Lindor KD. Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management. Clin Liver Dis. 2013 May; 17 (2):269-77 Epub 2012 Dec 20
    View PubMed
  62. Eaton JE, Talwalkar JA. Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep. 2013 Mar 1; 12 (1):28-36
    View PubMed
  63. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013 Mar; 37 (6):604-12 Epub 2013 Feb 05
    View PubMed
  64. Imam MH, Talwalkar JA, Lindor KD. An update on primary sclerosing cholangitis:from pathogenesis to treatment. Minerva Gastroenterol Dietol. 2013 Mar; 59(1):49-58.
    View PubMed
  65. Dzyubak B, Venkatesh SK, Glaser K, Yin M, Talwalkar J, Chen J, Chen J, Manduca A, Ehman RL. Stable Automated Segmentation of Liver MR Elastography Images for Clinical Stiffness Measurement. Proc SPIE Int Soc Opt Eng. 2013 Feb 9; 8672
    View PubMed
  66. Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani N, Fontana RJ, Watkins PB, Lee WM, Reddy KR, Stolz A, Talwalkar J, Davern T, Saha D, Bell LN, Barnhart H, Gu J, Serrano J, Bonkovsky HL. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One. 2013; 8 (12):e81974 Epub 2013 Dec 27
    View PubMed
  67. Leise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep. 2013 Jan; 15 (1):300
    View PubMed
  68. Chen J, Yin M, Glaser KJ, Talwalkar JA, Ehman RL. MR elastography of liver disease: State of the art. Appl Radiol. 2013; 42(4):5-12.
    View PubMed
  69. Tabibian JH, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int. 2013; 2013:389537 Epub 2013 Oct 22
    View PubMed
  70. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB, Drug-Induced Liver Injury Network, Diligen, Eudragene, Spanish DILI Registry, International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012 Nov; 22(11):784-95.
    View PubMed
  71. Gossard AA, Talwalkar JA. A 48-year-old woman with a new diagnosis of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2012 Sep; 10(9):980-3. Epub 2012 May 18.
    View PubMed
  72. Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ, Hay JE, Wiesner RH, Gores GJ, Rosen CB, Heimbach JK, Charlton MR. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012 Jul; 18 (7):803-10
    View PubMed
  73. Hoganson DD, Chen J, Chen J, Ehman RL, Talwalkar JA, Michet CJ Jr, Yin M, Crowson CS, Matteson EL. Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment. Open J Rheumatol Autoimmune Dis. 2012 May; 2 (2):6-13
    View PubMed
  74. Sethi S, Simonetto DA, Abdelmoneim SS, Campion MB, Kaloiani I, Clayton AC, Kremers WK, Halling KC, Kamath PS, Talwalkar J, Shah VH. Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. J Clin Exp Hepatol. 2012 Mar; 2 (1):19-26 Epub 2012 Apr 12
    View PubMed
  75. Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012 Mar; 18 (3):323-31
    View PubMed
  76. Talwalkar JA, Swanson KL, Krowka MJ, Andrews JC, Kamath PS. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology. 2011 Nov; 141 (5):1673-9 Epub 2011 June 30
    View PubMed
  77. Guha IN, Myers RP, Patel K, Talwalkar JA. Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology. 2011 Oct; 54(4):1454-62. Epub 2011 Aug 09.
    View PubMed
  78. Shire NJ, Yin M, Chen J, Railkar RA, Fox-Bosetti S, Johnson SM, Beals CR, Dardzinski BJ, Sanderson SO, Talwalkar JA, Ehman RL. Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging. 2011 Oct; 34(4):947-55. Epub 2011 Jul 12.
    View PubMed
  79. Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am. 2011 Sep; 40 (3):507-21
    View PubMed
  80. Bielinski SJ, Chai HS, Pathak J, Talwalkar JA, Limburg PJ, Gullerud RE, Sicotte H, Klee EW, Ross JL, Kocher JP, Kullo IJ, Heit JA, Petersen GM, de Andrade M, Chute CG. Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc. 2011 Jul; 86 (7):606-14 Epub 2011 June 06
    View PubMed
  81. Nedredal GI, Yin M, McKenzie T, Lillegard J, Luebke-Wheeler J, Talwalkar J, Ehman R, Nyberg SL. Portal hypertension correlates with splenic stiffness as measured with MR elastography. J Magn Reson Imaging. 2011 Jul; 34 (1):79-87 Epub 2011 May 23
    View PubMed
  82. Yin M, Talwalkar JA, Glaser KJ, Venkatesh SK, Chen J, Manduca A, Ehman RL. Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease. AJR Am J Roentgenol. 2011 Jul; 197 (1):64-70
    View PubMed
  83. Anaparthy R, Talwalkar JA, Yin M, Roberts LR, Fidler JL, Ehman RL. Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. Aliment Pharmacol Ther. 2011 Jul; 34 (1):83-91 Epub 2011 May 03
    View PubMed
  84. Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. Hepatology. 2011 Jun; 53 (6):2107-10
    View PubMed
  85. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011 Jun; 259 (3):749-56 Epub 2011 Apr 01
    View PubMed
  86. Bjornsson E, Talwalkar J, Treeprasertsuk S, Neuhauser M, Lindor K. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol. 2011 Jan; 9(1):57-63. Epub 2010 Aug 17.
    View PubMed
  87. Liu SS, Schneekloth TD, Talwalkar JA, Kim WR, Poterucha JJ, Charlton MR, Wiesner RH, Gross JB. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep; 44 (8):e178-85
    View PubMed
  88. Bjornsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010 Jun; 51(6):2040-8.
    View PubMed
  89. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010 Apr; 10 (4):720-726 Epub 2010 Feb 25
    View PubMed
  90. Abdelmoneim SS, Talwalkar J, Sethi S, Kamath P, Fathalla MM, Kipp BR, Campion MB, Clayton AC, Halling KC, Shah VH. A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension. Liver Int. 2010 Feb; 30 (2):191-7 Epub 2009 Oct 19
    View PubMed
  91. Neuhauser M, Bjornsson E, Treeprasertsuk S, Enders F, Silveira M, Talwalkar J, Lindor K. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol. 2010 Feb; 105(2):345-53. Epub 2009 Nov 03.
    View PubMed
  92. Bjornsson E, Kalaitzakis E, Neuhauser M, Enders F, Maetzel H, Chapman RW, Talwalkar J, Lindor K, Jorgensen R. Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. Liver Int. 2010 Feb; 30(2):251-8. Epub 2009 Nov 17.
    View PubMed
  93. Charatcharoenwitthaya P, Talwalkar JA, Angulo P, Gossard AA, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb; 55 (2):476-83 Epub 2009 Mar 03
    View PubMed
  94. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol. 2010 Jan; 34(1):27-34.
    View PubMed
  95. Talwalkar JA. Antifibrotic therapies--emerging biomarkers as treatment end points. Nat Rev Gastroenterol Hepatol. 2010 Jan; 7 (1):59-61
    View PubMed
  96. Talwalkar JA, Yin M, Venkatesh S, Rossman PJ, Grimm RC, Manduca A, Romano A, Kamath PS, Ehman RL. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. AJR Am J Roentgenol. 2009 Jul; 193 (1):122-7
    View PubMed
  97. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009 May 5; 100 (9):1385-92
    View PubMed
  98. Yin M, Chen J, Glaser KJ, Talwalkar JA, Ehman RL. Abdominal magnetic resonance elastography. Top Magn Reson Imaging. 2009 Apr; 20 (2):79-87
    View PubMed
  99. Bucuvalas JC, Alonso E, Magee JC, Talwalkar J, Hanto D, Doo E. Improving long-term outcomes after liver transplantation in children. Am J Transplant. 2008 Dec; 8(12):2506-13. Epub 2008 Oct 06.
    View PubMed
  100. Venkatesh SK, Yin M, Glockner JF, Takahashi N, Araoz PA, Talwalkar JA, Ehman RL. MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol. 2008 Jun; 190 (6):1534-40
    View PubMed
  101. Llovet JM, Di Bisceglie, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21; 100(10):698-711. Epub 2008 May 13
    View PubMed
  102. Perri RE, Chiorean MV, Fidler JL, Fletcher JG, Talwalkar JA, Stadheim L, Shah ND, Kamath PS. A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology. 2008 May; 47: (5)1587-94.
    View PubMed
  103. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology. 2008 Jan; 47: (1)332-42.
    View PubMed
  104. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007 Oct; 5 (10):1214-20
    View PubMed
  105. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, Fidler JL, Ehman RL. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007 Oct; 5 (10):1207-1213.e2
    View PubMed
  106. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007 Sep; 13(9):1236-45.
    View PubMed
  107. Perri R, Assi M, Talwalkar J, Heimbach J, Hogan W, Moore SB, Rosen CB. Graft vs. host disease after liver transplantation: a new approach is needed. Liver Transpl. 2007 Aug; 13(8):1092-9.
    View PubMed
  108. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol. 2007 Jun; 31(6):907-13.
    View PubMed
  109. Panjala C, Talwalkar JA, Lindor KD. Risk of lymphoma in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007 Jun; 5(6):761-4.
    View PubMed
  110. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007 Jun; 102(6):1244-50. Epub 2007 Feb 23.
    View PubMed
  111. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int. 2007 May; 27 (4):451-3
    View PubMed
  112. Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol. 2007 May-Jun; 41(5):494-500.
    View PubMed
  113. Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM, Plevak DJ, Talwalkar JA, Kim WR, Kamath PS. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007 Apr; 132(4):1261-9.
    View PubMed
  114. Talwalkar JA. Shall we bury the sword? Imaging of hepatic fibrosis. Gastroenterology. 2006 Dec; 131(6):1669-71.
    View PubMed
  115. Talwalkar JA, Donlinger JJ, Gossard AA, Keach JC, Jorgensen RA, Petz JC, Lindor KD. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci. 2006 Nov; 51 (11):1985-91 Epub 2006 Oct 20
    View PubMed
  116. Meves A, el-Azhary RA, Talwalkar JA, Moore SB, Brewer JD, Motsonelidze C, McNallan KT, Reed AM, Rosen CB. Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. J Am Acad Dermatol. 2006 Oct; 55(4):642-6.
    View PubMed
  117. Talwalkar JA. Cost-effectiveness of treating esophageal varices. Clin Liver Dis. 2006 Aug; 10(3):679-89, xi.
    View PubMed
  118. Talwalkar JA. Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis. Gastroenterology. 2006 Mar; 130(3):1005-7.
    View PubMed
  119. Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am. 2006 Mar; 35 (1):201-19
    View PubMed
  120. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006 Mar; 40 Suppl 1:S34-8
    View PubMed
  121. Talwalkar JA. Cost-effectiveness analyses on primary prophylaxis for esophageal variceal bleeding. Clin Liv Dis. 2006; 10:679-89.
  122. Talwalkar JA. Enhancing the role of internal medicine subspecialty societies in defining quality of care. Minn Med. 2006 Jan; 89(1):42-5.
    View PubMed
  123. Sanchez W, Talwalkar JA, Gores GJ. "Will all liver transplantation patients eventually die from cancer?". J Hepatol. 2006 Jan; 44(1):13-8. Epub 2005 Nov 07.
    View PubMed
  124. Ghali P, Talwalkar JA. The spectrum of nonalcoholic fatty liver disease. Journal of Clinical Outcomes Management. 2005 Nov; 12(11):585-95.
  125. Talwalkar JA, Kamath PS. Influence of recent advances in medical management on clinical outcomes of cirrhosis. Mayo Clin Proc. 2005 Nov; 80(11):1501-8.
    View PubMed
  126. Talwalkar JA. Determining the extent of quality health care for hospitalized patients with cirrhosis. Hepatology. 2005 Aug; 42(2):492-4.
    View PubMed
  127. Slijkhuis WA, Stadheim L, Hassoun ZM, Nzeako UC, Kremers WK, Talwalkar JA, Gores GJ. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol. 2005 Apr; 39 (4):333-8
    View PubMed
  128. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2005 Feb; 39: (2)168-71.
    View PubMed
  129. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2005 Feb; 100: (2)308-12.
    View PubMed
  130. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis. 2005 Jan; 11 (1):62-72
    View PubMed
  131. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology. 2004 Nov; 127 (5 Suppl 1):S126-32
    View PubMed
  132. Talwalkar JA, Angulo P, Johnson CD, Petersen BT, Lindor KD. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology. 2004 Jul; 40(1):39-45.
    View PubMed
  133. Talwalkar JA, Kamath PS. An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis. Am J Med. 2004 Jun 1; 116(11):759-66.
    View PubMed
  134. Jauhar S, Talwalkar JA, Schneekloth T, Jowsey S, Wiesner RH, Menon KVN. Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl. 2004 Mar; 10(3):408-11.
    View PubMed
  135. Talwalkar JA, Kamath PS. Identifying effective uses of B-blocker therapy in cirrhosis. Am J Med. 2004(116):759-66.
  136. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV Jr, Yawn BP, Dickson ER, Melton LJ 3rd, Melton LJ. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003 Nov; 125 (5):1364-9
    View PubMed
  137. Talwalkar JA. An evidence-based approach to studies in cirrhosis and portal hypertension: medical management of mild to moderate ascites. Clin Gastroenterol Hepatol. 2003 Nov; 1 (6):474-9
    View PubMed
  138. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003 Jul 5; 362(9377):53-61.
    View PubMed
  139. Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003 Jul; 1(4):297-302.
    View PubMed
  140. Talwalkar JA, Kim WR, Rosen CB, Kamath PS, Wiesner RH. Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis. Mayo Clin Proc. 2003 Apr; 78 (4):431-5
    View PubMed
  141. Sedlack RE, Smyrk TC, Czaja AJ, Talwalkar JA. Celiac disease - Associated autoimmune cholangitis. Am J Gastroenterol. 2002 Dec; 97(12):3196-8.
    View PubMed
  142. Talwalkar JA. Motion - all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol. 2002 Oct; 16 (10):718-21
    View PubMed
  143. Talwalkar JA, Lindor KD. Sclerosing cholangitis. Curr Opin Gastroenterol. 2002 May; 18 (3):372-7
    View PubMed
  144. Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol. 2002 May; 97(5):1191-7.
    View PubMed
  145. Talwalkar JA, Ruymann FW, Marcoux P, Farraye FA. Recurrent thrombotic thrombocytopenic purpura (TTP) as a complication of acute relapsing pancreatitis. Dig Dis Sci. 2002 May; 47 (5):1096-9
    View PubMed
  146. Talwalkar JA, Lindor KD. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001 Aug; 15(4):563-75.
    View PubMed
  147. Talwalkar JA, Lindor KD. Cholestatic liver disease. Pract Gastroenterol. 2001; 25(1):28-35.
  148. Talwalkar JA, Seaberg E, Kim WR, Wiesner RH. Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and Child-Pugh score. Liver Transpl. 2000 Nov; 6(6):753-758.
    View PubMed
  149. Talwalkar JA, Soetikno RM, Carr-Locke DL, Berg CL. Severe cholestasis related to itraconazole use for the treatment of onychomycosis. Am J Gastroenterol. 2000; 94:3632-3.
  150. Talwalkar JA, VanDam J. Setback for systemic therapy of esophageal cancer: right concept, disappointing result. Gastroenterology. 1999; 117:1020-2,.
    View PubMed
PST-20221329